Pedram Razavi

31PUBLICATIONS
270CO-AUTHORS
Environmental epidemiologyCancer geneticsHaematological tumoursMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (31)

|May 05, 2026
Benralizumab for Eosinophil-Related Cutaneous Adverse Events of Anticancer Therapy: A Phase II Trial.

|Mar 04, 2026
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer.

Anton Safonov, Minna Lee, David N Brown

|Feb 23, 2026
Evolution of oncogene amplification across 86,000 cancer cell genomes.

Jake June-Koo Lee, Sohrab Salehi, Matthew A Myers

|Dec 12, 2025
Publisher Correction: APOBEC3 mutagenesis drives therapy resistance in breast cancer.

Avantika Gupta, Andrea Gazzo, Pier Selenica

|Nov 10, 2025
Machine Learning-Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2- Early Breast Cancer Using Real-World and NATALEE Data.

Frederick M Howard, Peter A Fasching, Cesar A Santa-Maria

|Nov 10, 2025
Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding.

Wanyi Chen, Avantika Gupta, Nicholas Mai

Pageof 6